|
|
Volumn 147, Issue 11, 2007, Pages 813-
|
|
Risks of intravenous immunoglobulin in sepsis affect trial design
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
IMMUNOGLOBULIN;
IMMUNOLOGICAL ADJUVANT;
DRUG CONTRAINDICATION;
DRUG EFFECT;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INFUSION;
DRUG MECHANISM;
DRUG USE;
HUMAN;
IMMUNE DEFICIENCY;
LETTER;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SEPSIS;
SIDE EFFECT;
ADULT;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
RISK FACTOR;
ADJUVANTS, IMMUNOLOGIC;
ADULT;
HUMANS;
IMMUNOGLOBULINS, INTRAVENOUS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK FACTORS;
SEPSIS;
|
|
EID: 38449114781
PISSN: 00034819
EISSN: None
Source Type: Journal
DOI: 10.7326/0003-4819-147-11-200712040-00017 Document Type: Letter |
|
Times cited : (4)
|
|
References (6)
|
